---
title: "Revolution Medicines Q2 FY26 net loss widens to $644.4 million; R&D expenses rise to $394.9 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295008649.md"
description: "Revolution Medicines reported a widened Q2 FY26 GAAP net loss of $644.4 million, up from $247.8 million prior year. R&D expenses rose to $394.9 million due to increased trial and manufacturing costs for daraxonrasib and zoldonrasib. G&A expenses also increased to $110.2 million. The company holds $3.9 billion in cash and securities. Additionally, the FDA accepted the NDA for daraxonrasib for metastatic pancreatic cancer, and operating expense guidance was updated."
datetime: "2026-08-05T20:17:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295008649.md)
  - [en](https://longbridge.com/en/news/295008649.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295008649.md)
generator: "portal-rs"
---

# Revolution Medicines Q2 FY26 net loss widens to $644.4 million; R&D expenses rise to $394.9 million

-   Revolution Medicines posted a GAAP net loss of $644.4 million for Q2 2026, widening from a $247.8 million loss a year earlier. \* GAAP R&D expense climbed to $394.9 million from $224.1 million, driven by higher daraxonrasib and zoldonrasib trial and manufacturing costs. \* GAAP G&A expense rose to $110.2 million from $40.6 million on higher stock-based compensation, added headcount, and commercial preparation activities. \* Cash, cash equivalents and marketable securities totaled $3.9 billion at June 30, 2026, reflecting April equity and 0.50% convertible senior notes offerings and a $250 million Royalty Pharma payment. \* Updated 2026 GAAP operating expense guidance to $2.1-$2.2 billion; FDA accepted daraxonrasib NDA for previously treated metastatic pancreatic cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051602PRIMZONEFULLFEED9804460) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)

## Related News & Research

- [BUZZ-Street View: Revolution's pancreatic cancer drug nod sparks a 'transformative' era](https://longbridge.com/en/news/297178071.md)
- [Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug](https://longbridge.com/en/news/297079354.md)
- [Revolution Medicines wins FDA approval for RASONQUE in previously treated metastatic pancreatic cancer](https://longbridge.com/en/news/297075865.md)
- [RVMD: FDA accepted daraxonrasib NDA; net loss rose to $644M, cash reserves reached $3.9B](https://longbridge.com/en/news/295007515.md)
- [Erasca says FDA grants fast-track status to ERAS-0015 for metastatic pancreatic cancer](https://longbridge.com/en/news/296784766.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**